To this end, Zhang and colleagues have demonstrated that targeting CDK1 is an effective strategy to enhance the efficacy of MEK inhibition in mutant BRAF colorectal cancer cell lines and tumor xenografts28, consistent with a previous report on the relevance of CDK1 as a therapeutic target in human colorectal cancers29. The gene discussed is BRAF; the disease is colorectal cancer.